Anti-Amyloid Monoclonal (Early AD)

Edit / manage →

Alzheimer disease

Phase 2Clinical entryMonoclonal antibodyNeurodegenerationMixed· medium conf4 evidence-linked claims

Overview

Disease area: Neurodegeneration
Indication: Alzheimer diseaseMONDO:0004975
Mechanism of action: Protofibril-selective amyloid-beta clearance
Development stage: Phase 2
Institution: Summit Pulmonary Research Group
Principal investigators: M. Castellano
Targets: APPMAPT
Pathways: Amyloid clearance
Trial registry: —

Scientific assessment

1 claims

Supporting EvidenceModerate
Protofibril-selective amyloid clearance produced significant amyloid PET reduction and slowed decline in early AD.
publicationPMID:36449413· 2023-01-05

Translational assessment

1 claims

BiomarkersModerate
Amyloid PET and plasma p-tau217 enable enrichment and treatment monitoring in early symptomatic AD.
publicationPMID:37224516

Regulatory assessment

0 claims

No evidence linked yet.

Commercial assessment

1 claims

Standard of CareLimited
Class adoption is gated by ARIA monitoring burden and infusion logistics; subcutaneous dosing would be a differentiator.
internalsoc-2024

Execution assessment

1 claims

Operational RisksModerate
ARIA-E/H risk requires MRI surveillance infrastructure and APOE4 stratification, raising trial operational complexity.
internalrisk-ad

Structured reviews

1 reviews

Mixed· medium confAcademicCognitive neurology panel2025-02-14

Strengths

Demonstrated amyloid reduction and slowed decline.

Weaknesses

ARIA monitoring burden; modest clinical effect size.

Improvement areas

Pursue subcutaneous dosing and APOE4 stratification.

Internal rubric input (reviewer scoring — not a success probability)

Scientific validity

Translational readiness

Regulatory pathway

Commercial potential

Execution strength

Outcome

Clinical entry
Phase 2 in early symptomatic AD.2024-12-01

AI brief

flag off · defaultPhase 7

Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.

Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.